Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
122 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline landscape. Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.Bipolar Disorder (Manic Depression). Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Bipolar Disorder (Manic Depression) Overview 10 Therapeutics Development 11 Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11 Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12 Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13 Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 15 Bipolar Disorder (Manic Depression) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Bipolar Disorder (Manic Depression) - Products under Development by Companies 19 Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 21 Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 22 Aequus Pharmaceuticals Inc. 22 Amorsa Therapeutics Inc. 23 AstraZeneca Plc 24 Biogen Inc 25 Delpor, Inc. 26 Intas Pharmaceuticals Ltd. 27 Intra-Cellular Therapies, Inc. 28 Johnson & Johnson 29 KemPharm, Inc. 30 Mapi Pharma Ltd. 31 Navya Biologicals Pvt Ltd 32 Neurocrine Biosciences Inc 33 Omeros Corporation 34 Otsuka Holdings Co., Ltd. 35 Pfizer Inc. 36 Reviva Pharmaceuticals Inc. 37 SK Biopharmaceuticals Co., Ltd. 38 Sumitomo Dainippon Pharma Co Ltd 39 Zogenix, Inc. 40 Zysis Limited 41 Bipolar Disorder (Manic Depression) - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 (cycloserine + lurasidone hydrochloride) - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 aripiprazole - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 aripiprazole CR - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 aripiprazole ER - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 CB-1407 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 CB-2803 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Cenobamate - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 CNV-1061436 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 ebselen - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Endoxifen - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 ITI-007 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 JNJ-18038683 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 KP-303 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 lurasidone hydrochloride - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 NAV-003 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 paliperidone palmitate - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 PGW-5 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 quetiapine fumarate ER - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 risperidone - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 risperidone - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 risperidone - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 RP-5063 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 SKL-PSY - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Small Molecule for Bipolar Disorder - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Small Molecule for Cancer and Neurodegenerative Disease - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Small Molecule to Target GPR50 for Bipolar Disorder and Metabolic Disorders - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Small Molecules to Target NMDA Receptor for Bipolar Depression - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 ziprasidone mesylate - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Bipolar Disorder (Manic Depression) - Dormant Projects 104 Bipolar Disorder (Manic Depression) - Discontinued Products 107 Bipolar Disorder (Manic Depression) - Product Development Milestones 108 Featured News & Press Releases 108 Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia 108 Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office 109 Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress 110 Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan 111 Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition 111 May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression 112 May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association 113 Feb 25, 2016: Intra-Cellular Therapies Provides Product Update 114 Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch 116 Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression 116 Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder 117 Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch 118 Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole 119 Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder 120 May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole 120 Appendix 121 Methodology 121 Coverage 121 Secondary Research 121 Primary Research 121 Expert Panel Validation 121 Contact Us 121 Disclaimer 122
List of Tables
Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016 11 Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 22 Bipolar Disorder (Manic Depression) - Pipeline by Amorsa Therapeutics Inc., H2 2016 23 Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2016 24 Bipolar Disorder (Manic Depression) - Pipeline by Biogen Inc, H2 2016 25 Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2016 26 Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 27 Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 28 Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2016 29 Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2016 30 Bipolar Disorder (Manic Depression) - Pipeline by Mapi Pharma Ltd., H2 2016 31 Bipolar Disorder (Manic Depression) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 32 Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences Inc, H2 2016 33 Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2016 34 Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 35 Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2016 36 Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 37 Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 38 Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 39 Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2016 40 Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2016 41 Assessment by Monotherapy Products, H2 2016 42 Assessment by Combination Products, H2 2016 43 Number of Products by Stage and Target, H2 2016 45 Number of Products by Stage and Mechanism of Action, H2 2016 47 Number of Products by Stage and Route of Administration, H2 2016 49 Number of Products by Stage and Molecule Type, H2 2016 51 Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2016 104 Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2016 105 Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H2 2016 106 Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2016 107
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.